Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "FY26-earnings"

2 News Found

Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million
News | April 29, 2026

Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million

The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform

Pharma stocks face Q4 reality check amid global headwinds
News | April 20, 2026

Pharma stocks face Q4 reality check amid global headwinds

Analysts expect modest revenue growth but pressure on profitability in the March quarter

Latest Stories

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology

Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Head Bioprocessing, India, Avantor

Packaging